Fibroblast activation protein-targeted chimeric antigen-receptor-modified NK cells alleviate cardiac fibrosis

  • 0Department of Cardiology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650101, China.

|

|

Summary

This summary is machine-generated.

Engineered CAR natural killer (NK) cells targeting fibroblast activation protein (FAP) effectively reduced cardiac fibrosis in mice. This novel therapy shows promise for treating cardiovascular diseases by eliminating FAP-positive cells and improving heart function.

Area Of Science

  • Immunotherapy
  • Cardiovascular Research
  • Cell Biology

Background

  • Cardiac fibrosis (CF) is a key factor in cardiovascular disease progression, involving myofibroblast transdifferentiation.
  • Fibroblast activation protein (FAP) is a specific marker for activated myofibroblasts.
  • Chimeric antigen receptor (CAR)-based therapy offers a promising immunotherapy approach.

Purpose Of The Study

  • To construct CAR natural killer (NK) cells targeting FAP for potential CF therapy.
  • To evaluate the efficacy and mechanism of FAP-targeted CAR-NK cells in preclinical models of cardiac fibrosis.

Main Methods

  • Development of FAP-specific CAR-NK-92 cells.
  • In vitro assessment of FAP CAR-NK cell cytotoxicity, cytokine secretion, and degranulation against FAP+ cells and cardiac fibroblasts.
  • In vivo studies using a mouse model of Ang II/PE-induced cardiac injury.

Main Results

  • FAP CAR-NK-92 cells specifically recognized and killed FAP+ cells in vitro.
  • Enhanced cytotoxicity, cytokine secretion, and degranulation of FAP CAR-NK cells compared to parental NK-92 cells.
  • In vivo administration of FAP CAR-NK cells improved cardiac function and reduced fibrosis, with evidence of increased apoptosis in target cells.

Conclusions

  • FAP CAR-NK-92 cells demonstrate specific targeting and potent anti-fibrotic effects in vitro and in vivo.
  • This CAR-NK cell-based therapy represents a potential therapeutic strategy for cardiac fibrosis patients.